Loyens & Loeff advised and acted as legal counsel to Vifor Pharma on the sale of two potassium-containing, prescription medicinal products (Kalium Hausmann Effervetten and Kalium Hausmann KCL-retard) for Switzerland and Liechtenstein.

Vifor Pharma is one of the largest Swiss pharmaceutical companies and a global leader in the treatment of iron deficiency. Vifor Pharma has established a strong presence in the nephrology market and aims for global leadership in the segment of cardio-renal therapies. Vifor Pharma continued success is underpinned by a strong, diversified portfolio of commercial products and an exciting pipeline.

Loyens & Loeff advised Vifor Pharma on all Swiss legal aspects of the transaction. The team consisted of Andreas Hinsen (Local Partner Corporate / M&A), Gilles Pitschen (Associate Corporate / M&A) and Lara Pafumi (Junior Associate Corporate / M&A).